Search Results - "Kawata, Shuhei"
-
1
Five‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial
Published in Cancer science (01-10-2018)“…Although azacitidine is the first‐line drug for higher‐risk myelodysplastic syndrome (MDS) patients, its efficacy for lower‐risk MDS remains unestablished…”
Get full text
Journal Article -
2
Efficacy and surgical procedures of preoperative splenic artery embolization for laparoscopic splenectomy of a massive splenomegaly: A case report
Published in International journal of surgery case reports (01-01-2015)“…Highlights • The combination of embolization of the splenic artery and continuous epinephrine infusion to reduce the spleen volume was highly effective. • New…”
Get full text
Journal Article -
3
c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells
Published in Cardiovascular research (01-07-2007)“…The purpose of this study was to investigate whether c-Myc regulates expression of urokinase plasminogen activator (uPA) on hypoxia-induced vascular smooth…”
Get full text
Journal Article -
4
Relationship between expression of mutant type glutathione S-transferase theta-1 gene and reactivity of rapamycin in myelodysplastic syndrome
Published in Hematology (Luxembourg) (01-10-2009)“…We previously reported mRNA expression of glutathione S-transferases theta (GSTT)-1, wild type (623 bp) and mutant (500 bp), in patients with myelodysplastic…”
Get more information
Journal Article -
5
c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells
Published in Cardiovascular research (01-07-2007)Get full text
Journal Article